Is a complete EBS research report available?

No complete published report is available for Emergent BioSolutions Inc. (EBS) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Emergent BioSolutions Inc. (EBS)

NYSE: EBS · USD

$7.35

+0.04 (+0.6%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-30 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first EBS analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	379.2M
Revenue (ttm)	676.8M
Net income (ttm)	-8.6M
EPS (ttm)	-$0.21
Shares out	51.6M
Volume	572,637
Beta	2.34
Price target	$12.0	+63.3%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 676.8M
Net income (ttm): -8.6M
EPS (ttm): -$0.21
Market cap: 379.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All EBS indicators

Market & fundamental data

Available fields

243

Groups with data

Currency

USD

Showing 243 of 243 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001367644
Company name	Emergent BioSolutions Inc.
Country	United States
Country code	US
Cusip	29089Q105
Employees	900
Employees Change	-700%
Employees Change Percent	-43.75
Enterprise value	$806.1M
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
Industry PE	133.1
Industry PE Fwd	14.38
IPO Date	2006-11-15
Isin	US29089Q1058
Last refreshed	2026-07-30
Market cap	$379.2M
Market cap category	Small-Cap
Price	$7.35
Price currency	USD
Rev Per Employee	752,000x
Sector	Healthcare
Sector PE	45.6
Sector PE Fwd	24.3
Sic	2834
Symbol	EBS
Website	https://www.emergentbiosolutions.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-2.25%
EV Sales Forward	1.01x
EV/EBIT	13.28x
EV/EBITDA	4.92x
EV/FCF	5.95x
EV/Sales	1.19x
FCF yield	35.46%
P/B ratio	0.72x
P/S ratio	0.56x
PE Ratio10 Y	46.87x
PS Forward	0.48x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	8.97%
EBITDA Margin	24.22%
FCF margin	20.01%
Gross margin	47.49%
Gross Profit	$321.4M
Gross Profit Growth	10.67%
Gross Profit Growth Q	-38.38%
Gross Profit Growth3 Y	26.15%
Gross Profit Growth5 Y	-19.93%
Net Income	$-8.6M
Net Income Growth Q	-90%
Net Income Growth Years	2%
Pretax Margin	0.52%
Profit Margin	-1.27%
Profit Per Employee	$-9,556
Profitable Quarters	$1
Profitable Years	1
ROA	3.43
Roa5y	1.02
ROCE	5.18
ROE	-1.6
Roe5y	-19.53
ROIC	-20.02
Roic5y	0.76

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-13.33%
Cagr15y	-6.28%
Cagr1y	8.41%
Cagr3y	2.73%
Cagr5y	-35.37%
EPS Growth Q	-93.75
EPS Growth Years	2
FCF Growth	43.43%
FCF Growth5 Y	-15.29%
OCF Growth	34.42%
OCF Growth10 Y	-0.3%
OCF Growth5 Y	-21.08%
Revenue Growth	-29.89x
Revenue Growth Q	-29.75x
Revenue Growth Years	0x
Revenue Growth3 Y	-11.44x
Revenue Growth5 Y	-16.88x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.49
Assets	$1.3B
Cash	$160.3M
Current Assets	$637.6M
Current Liabilities	$148.7M
Debt	$584.6M
Debt EBITDA	$3.57
Debt Equity	$1.12
Debt FCF	$4.32
Equity	$523.1M
Interest Coverage	1.09
Liabilities	$797.3M
Long Term Assets	$682.8M
Long Term Liabilities	$648.6M
Net Cash	$-424.3M
Net Cash By Market Cap	$-111
Net Debt EBITDA	$2.59
Net Debt Equity	$0.81
Net Debt FCF	$3.13
Tangible Book Value	$52.7M
Tangible Book Value Per Share	$1.02
WACC	-7.38

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.29
Inventory Turnover	1.11
Net Working Capital	$331M
Quick ratio	1.9
Working Capital	$488.9M
Working Capital Turnover	$1.25

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.26%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-76.09%
1Y total return	8.41%
200-day SMA	9.63
3Y total return	8.41%
50-day SMA	8.11
50-day SMA vs 200-day SMA	50under200
5Y total return	-88.72%
All Time High	137.6
All Time High Change	-94.66%
All Time High Date	2020-08-06
All Time Low	1.42
All Time Low Change	417.61%
All Time Low Date	2024-02-06
ATR	0.31
Beta	2.34
Beta1y	3.01
Beta2y	2.8
Ch YTD	-40.53
High	7.46
High52	14.06
High52 Date	2026-01-07
High52ch	-47.72%
Low	7.19
Low52	5.62
Low52 Date	2025-08-04
Low52ch	30.9%
Ma50ch	-9.32%
Price vs 200-day SMA	-23.66%
RSI	38.21
RSI Monthly	43.73
RSI Weekly	41.15
Sharpe ratio	0.43x
Sortino ratio	0.82
Total Return	1.26%
Tr YTD	-40.53
Tr15y	-62.18%
Tr1m	-13.83%
Tr1w	-3.03%
Tr3m	-10.69%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$0.11
Earnings EPS Estimate Growth	-31.25
Earnings Revenue Estimate	179,400,000x
Earnings Revenue Estimate Growth	27.32x
Operating Income	$75.3M
Operating Income Growth Q	-79.17
Operating Income Growth5 Y	-34.02
Operating margin	11.13
Price target	$12
Price Target Change	$63.27

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	49,384,155%
Float Percent	95.71%
Net Borrowing	-112,500,000
Shares Insiders	4.29%
Shares Institutions	86.25%
Shares Out	51,596,296
Shares Qo Q	7.82%
Shares Yo Y	-1.26%
Short Float	20.94%
Short Ratio	10.15
Short Shares	20.04

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$118.8M
Adjusted OCF	131,400,000
Average Volume	684,345.4x
Bv Per Share	10.1
CAPEX	$-12.6M
Ch10y	-77.63
Ch15y	-64.61
Ch1m	-13.83
Ch1w	-3.03
Ch1y	8.41
Ch3m	-10.69
Ch3y	8.41
Ch5y	-88.72
Ch6m	-37.23
Change	0.55%
Change From Open	1.38
Close	7.31
Days Gap	-0.82
Depreciation Amortization	91,400,000
Dollar Volume	4,208,882
Earnings Date	2026-08-05
Earnings Time	amc
EBIT	$60.7M
EBITDA	$163.9M
EPS	$-0.21
F Score	5
FCF	$135.4M
FCF EV Yield	16.8x
FCF Per Share	$2.62
Financing CF	-147,600,000
Fiscal Year End	December
Founded	1,998
Income Tax	$12.1M
Investing CF	7,500,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-30
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-27
Ma150	9.29
Ma150ch	-20.88%
Ma20	7.79
Ma20ch	-5.65%
Net CF	8,700,000
Next Earnings Date	2026-08-05
Open	7.25
Optionable	Yes
P FCF Ratio	2.82
P FCF Ratio SBC	3.21
P OCF Ratio	2.58
P OCF Ratio SBC	2.91
Position In Range	59.26
Post Close	7.35
Postmarket Change Percent	-2.45
Postmarket Price	$7.17
Ppne	209,300,000
Price Date	2026-07-29
Price EBITDA	$2.33
Ptbv Ratio	7.25
Relative Volume	0.84x
Revenue	676,800,000x
SBC By Revenue	2.45x
Share Based Comp	16,600,000
Tax By Revenue	1.79x
Tax Rate	345.71%
Tr6m	-37.23%
Us State	Maryland
Volume	572,637
Z Score	1.33

Emergent BioSolutions Inc. (EBS)

Coverage state: Market snapshot only — no published research

Generate the first EBS analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · EBS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All EBS indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on EBS

Frequently asked questions